Skip to Main Content

Paper Details

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Oncoimmunology
11
2021
Author NameAffiliation
Craig L SlingluffUniversity of Virginia
Hussein A TawbiDept of Medicine and Hillman Cancer Center, University of Pittsburgh
Hussein A TawbiMD Anderson Cancer Center
John M KirkwoodDept of Medicine and Hillman Cancer Center, University of Pittsburgh
  • 1 - 4

Datasets

Release 1.2